Figure 1.
IUHCT of B6-GFP BM-MNCs conjugated with empty MLVs in Balb/c fetuses. (A) Experimental design: effect of empty MLV conjugation on ability of BM-MNCs to home and engraft post-IUHCT; group 1, unconjugated BM-MNC and group 2, DiD-labeled empty MLV-conjugated BM-MNCs. (B) Fetal survival 4 days post-IUHCT in both groups. Nanoparticle conjugation had no effect on fetal survival (group 1, 91% vs group 2, 100%). (C) Qualitative assessment of donor cell homing to liver, spleen, and thymus by fluorescent stereotactic microscopy (4 days post-IUHCT) demonstrated no differences between experimental groups. (D) Quantitative confirmation of donor cell engraftment (4 days post-IUHCT) using flow cytometry (liver: group 1, 20.6% ± 2.1% vs group 2, 18.3% ± 1.9%; spleen: group 1, 26.1% ± 2.1% vs group 2, 27.7% ± 2.9%; thymus: group 1, 0.8% ± 0.1% vs group 2, 0.7% ± 0.1%). E18, embryonic day 18; IUT, in utero transplantation.

IUHCT of B6-GFP BM-MNCs conjugated with empty MLVs in Balb/c fetuses. (A) Experimental design: effect of empty MLV conjugation on ability of BM-MNCs to home and engraft post-IUHCT; group 1, unconjugated BM-MNC and group 2, DiD-labeled empty MLV-conjugated BM-MNCs. (B) Fetal survival 4 days post-IUHCT in both groups. Nanoparticle conjugation had no effect on fetal survival (group 1, 91% vs group 2, 100%). (C) Qualitative assessment of donor cell homing to liver, spleen, and thymus by fluorescent stereotactic microscopy (4 days post-IUHCT) demonstrated no differences between experimental groups. (D) Quantitative confirmation of donor cell engraftment (4 days post-IUHCT) using flow cytometry (liver: group 1, 20.6% ± 2.1% vs group 2, 18.3% ± 1.9%; spleen: group 1, 26.1% ± 2.1% vs group 2, 27.7% ± 2.9%; thymus: group 1, 0.8% ± 0.1% vs group 2, 0.7% ± 0.1%). E18, embryonic day 18; IUT, in utero transplantation.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal